BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 22899582)

  • 21. Long-term safety and activity of cladribine in patients with extranodal B-cell marginal zone lymphoma of the mucosa-associated lymphoid tissue (MALT) lymphoma.
    Kiesewetter B; Dolak W; Simonitsch-Klupp I; Mayerhoefer ME; Raderer M
    Hematol Oncol; 2017 Jun; 35(2):177-186. PubMed ID: 26580149
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Translocation t(11;18)(q21;q21) is not predictive of response to chemotherapy with 2CdA in patients with gastric MALT lymphoma.
    Streubel B; Ye H; Du MQ; Isaacson PG; Chott A; Raderer M
    Oncology; 2004; 66(6):476-80. PubMed ID: 15452377
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial.
    Durie BGM; Hoering A; Abidi MH; Rajkumar SV; Epstein J; Kahanic SP; Thakuri M; Reu F; Reynolds CM; Sexton R; Orlowski RZ; Barlogie B; Dispenzieri A
    Lancet; 2017 Feb; 389(10068):519-527. PubMed ID: 28017406
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rituximab plus bendamustine is active in pretreated patients with extragastric marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma).
    Kiesewetter B; Mayerhoefer ME; Lukas J; Zielinski CC; Müllauer L; Raderer M
    Ann Hematol; 2014 Feb; 93(2):249-53. PubMed ID: 23925930
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High-dose clarithromycin is an active monotherapy for patients with relapsed/refractory extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT): the HD-K phase II trial.
    Ferreri AJ; Sassone M; Kiesewetter B; Govi S; Scarfò L; Donadoni G; Raderer M
    Ann Oncol; 2015 Aug; 26(8):1760-5. PubMed ID: 25935794
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue of the head and neck area: high rate of disease recurrence following local therapy.
    Wenzel C; Fiebiger W; Dieckmann K; Formanek M; Chott A; Raderer M
    Cancer; 2003 May; 97(9):2236-41. PubMed ID: 12712477
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Beta-2-microglobulin levels in patients with extranodal B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT)-type: a retrospective analysis.
    Penz MZ; Fiebiger WC; Valencak JB; Osterreicher C; Ba-Ssalamah A; Formanek M; Brodowic T; Chott A; Raderer M
    Anticancer Res; 2001; 21(4B):3049-52. PubMed ID: 11712809
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Experience with clarithromycin as antineoplastic therapy for extranodal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue (MALT-lymphoma) outside of clinical trials: Real-world data from the University of Vienna.
    Pokorny A; Kiesewetter B; Raderer M
    Hematol Oncol; 2020 Aug; 38(3):409-411. PubMed ID: 32347560
    [No Abstract]   [Full Text] [Related]  

  • 29. Long-term analysis of phase II studies of single-agent lenalidomide in relapsed/refractory mantle cell lymphoma.
    Witzig TE; Luigi Zinzani P; Habermann TM; Tuscano JM; Drach J; Ramchandren R; Kalayoglu Besisik S; Takeshita K; Casadebaig Bravo ML; Zhang L; Fu T; Goy A
    Am J Hematol; 2017 Oct; 92(10):E575-E583. PubMed ID: 28699256
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Marginal zone lymphoma (low-grade B-cell lymphoma of mucosa-associated lymphoid tissue type) of skin and subcutaneous tissue: a study of 15 patients.
    Bailey EM; Ferry JA; Harris NL; Mihm MC; Jacobson JO; Duncan LM
    Am J Surg Pathol; 1996 Aug; 20(8):1011-23. PubMed ID: 8712288
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combination therapy with rituximab and intravenous or oral fludarabine in the first-line, systemic treatment of patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type.
    Salar A; Domingo-Domenech E; Estany C; Canales MA; Gallardo F; Servitje O; Fraile G; Montalbán C
    Cancer; 2009 Nov; 115(22):5210-7. PubMed ID: 19672998
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Final report of a phase 2 clinical trial of lenalidomide monotherapy for patients with T-cell lymphoma.
    Toumishey E; Prasad A; Dueck G; Chua N; Finch D; Johnston J; van der Jagt R; Stewart D; White D; Belch A; Reiman T
    Cancer; 2015 Mar; 121(5):716-23. PubMed ID: 25355245
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplantation: an open label, single-arm, multicentre phase 2 trial.
    Ferreri AJ; Sassone M; Zaja F; Re A; Spina M; Rocco AD; Fabbri A; Stelitano C; Frezzato M; Rusconi C; Zambello R; Couto S; Ren Y; Arcari A; Bertoldero G; Nonis A; Scarfò L; Calimeri T; Cecchetti C; Chiozzotto M; Govi S; Ponzoni M
    Lancet Haematol; 2017 Mar; 4(3):e137-e146. PubMed ID: 28219694
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma.
    Fehniger TA; Larson S; Trinkaus K; Siegel MJ; Cashen AF; Blum KA; Fenske TS; Hurd DD; Goy A; Schneider SE; Keppel CR; Wagner-Johnston ND; Carson KR; Bartlett NL
    Blood; 2011 Nov; 118(19):5119-25. PubMed ID: 21937701
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Absence of efficacy of thalidomide monotherapy in patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma).
    Troch M; Zielinski C; Raderer M
    Ann Oncol; 2009 Aug; 20(8):1446-7. PubMed ID: 19654203
    [No Abstract]   [Full Text] [Related]  

  • 36. Ocular adnexal lymphoma. A clinicopathologic study with identification of lymphomas of mucosa-associated lymphoid tissue type.
    White WL; Ferry JA; Harris NL; Grove AS
    Ophthalmology; 1995 Dec; 102(12):1994-2006. PubMed ID: 9098307
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase II study of oxaliplatin for treatment of patients with mucosa-associated lymphoid tissue lymphoma.
    Raderer M; Wöhrer S; Bartsch R; Prager G; Drach J; Hejna M; Gaiger A; Turetschek K; Jaeger U; Streubel B; Zielinski CC
    J Clin Oncol; 2005 Nov; 23(33):8442-6. PubMed ID: 16293875
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chemoimmunotherapy for Mucosa-Associated Lymphoid Tissue-Type Lymphoma: A Review of the Literature.
    Kiesewetter B; Ferreri AJ; Raderer M
    Oncologist; 2015 Aug; 20(8):915-25. PubMed ID: 26156327
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of low grade gastric mucosa-associated lymphoid tissue lymphoma in stage I with Helicobacter pylori eradication. Long-term results after sequential histologic and molecular follow-up.
    Montalban C; Santon A; Boixeda D; Redondo C; Alvarez I; Calleja JL; de Argila CM; Bellas C
    Haematologica; 2001 Jun; 86(6):609-17. PubMed ID: 11418369
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma.
    Witzig TE; Vose JM; Zinzani PL; Reeder CB; Buckstein R; Polikoff JA; Bouabdallah R; Haioun C; Tilly H; Guo P; Pietronigro D; Ervin-Haynes AL; Czuczman MS
    Ann Oncol; 2011 Jul; 22(7):1622-1627. PubMed ID: 21228334
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.